Table 1.
Summary of patient characteristics, imaging findings and survival
| Patient characteristics and imaging findings | n (%) | Median (range) |
|---|---|---|
| Gender | ||
| Male | 7 (37%) | |
| Female | 12 (63%) | |
| Age at diagnosis (years) | ||
| <5 | 3 (16%) | 7 (3-10) |
| 5-8 | 12 (63%) | |
| >8 | 4 (21%) | |
| Histological and molecular data | ||
| DA, H3K27M-wt | 1 (5%) | |
| AA, H3K27M-wt | 1 (5%) | |
| AA, H3K27M-m | 4 (21%) | |
| GB, H3K27M-m | 4 (21%) | |
| ND | 9 (48%) | |
| Ring enhancement | ||
| Y | 6 (31.6%) | |
| N | 13 (68.4%) | |
| 18-F-DOPA uptake patterns | ||
| T/N≤1 | 4 (21%) | T/S 0.44 (0.24-0.55) |
| T/N>1-T/S≤1 | 2 (10.5%) | T/S 0.81 (0.70-0.93) |
| T/S >1 | 13 (68.5%) | T/S 1.27 (1.06-2.32) |
| Imaging findings and OS according to PET semi-quantification | ||
| Pre-treatment MRI tumor volume (cc) | 27.64 (18.58-55.63) | |
| T/N≤1 | 39.51 (31.46-55.63) | |
| T/N>1-T/S≤1 | 25.04 (25.03-25.06) | |
| T/S >1 | 27.21 (18.58-46.35) | |
| Post-treatment MRI tumor volume (cc) | 20 (7-42) | |
| T/N≤1 | 13.77 (7-20.54) | |
| T/N>1-T/S≤1 | 9.81 (8.35-11.27) | |
| T/S >1 | 22 (11.18-42) | |
| Pre-treatment PET tumor volume (cc) | 17.2 (0.86-31) | |
| T/N≤1 | No increased uptake | |
| T/N>1-T/S≤1 | 6 (4-8) | |
| T/S >1 | 18 (0.86-31) | |
| Pre-treatment PET uniformity (%) | 52.5 (3.94-92.57) | |
| T/N≤1 | No increased uptake | |
| T/N>1-T/S≤1 | 23.96% (15.96-31.96%) | |
| T/S >1 | 62.56% (3.94-92.57%) | |
| Overall survival (months) | 10 (5-38) | |
| T/S≤1 | 23 (16-38) | |
| T/S >1 | 9 (5-12) | |
DA: diffuse astrocytoma, AA: anaplastic astrocytoma, GB: glioblastoma, wt: wildtype, m: mutant, ND: not done, Y: yes, N: no.